Fresenius Medical Care (NYSE:FMS) Shares Gap Down – Should You Sell?

Fresenius Medical Care AG (NYSE:FMS)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $20.39, but opened at $19.47. Fresenius Medical Care shares last traded at $19.59, with a volume of 96,088 shares traded.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on FMS. StockNews.com began coverage on shares of Fresenius Medical Care in a research note on Tuesday, October 8th. They set a “strong-buy” rating for the company. Truist Financial upped their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $23.00.

Fresenius Medical Care Stock Down 5.7 %

The firm has a market cap of $11.28 billion, a price-to-earnings ratio of 22.91, a P/E/G ratio of 1.11 and a beta of 0.91. The firm’s fifty day moving average is $20.31 and its two-hundred day moving average is $20.18. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. The company had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. On average, sell-side analysts expect that Fresenius Medical Care AG will post 1.52 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care

Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning raised its holdings in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after buying an additional 6,373 shares during the period. Wulff Hansen & CO. increased its holdings in shares of Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the period. QRG Capital Management Inc. increased its holdings in shares of Fresenius Medical Care by 19.5% in the 1st quarter. QRG Capital Management Inc. now owns 54,363 shares of the company’s stock valued at $1,048,000 after purchasing an additional 8,870 shares during the period. SG Americas Securities LLC increased its holdings in Fresenius Medical Care by 50.0% in the first quarter. SG Americas Securities LLC now owns 15,228 shares of the company’s stock worth $294,000 after buying an additional 5,078 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC bought a new stake in Fresenius Medical Care during the first quarter worth approximately $584,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.